
Press Release

14 November 2018

CESC launches CES HK Biotechnology Index

China Exchanges Services Company Limited (CESC) has today (Wednesday) announced the launch of its new CES HK Biotechnology Index. This new index is designed to reflect the performance of biotech companies listed in Hong Kong.

The CES HK Biotechnology Index is the first to track shares of biotech companies, including pre-revenue biotech companies, with a primary or secondary listing on Hong Kong's Main Board.

“Biotechnology is an exciting and innovative industry, where technology can play a significant and notable role and where a long-term informed view is needed from investors,” said CESC Chief Executive Mao Zhirong. “Hong Kong is increasingly becoming known as a global biotechnology hub, and this new index comes as the market seeks new ways to analyse this industry, and as investors look to diversify their portfolios. The launch of the Index is the next vital step as we continue to build a strong biotech investment ecosystem.”

For more information about CESC's new index, please refer to Appendix 1 and 2.

About CESC

CESC is a joint venture formed and equally owned by Hong Kong Exchanges and Clearing Limited, the Shanghai Stock Exchange and the Shenzhen Stock Exchange. Its aim is to contribute to the development of China's capital markets. Registered and incorporated in Hong Kong, CESC was officially launched in September 2012 and commenced operations on 30 October. CESC's principal businesses include compiling cross-border indices based on products traded on the Hong Kong and Mainland securities markets, developing industry classifications for listed companies, and developing information standards and information products. CESC also develops financial products to link the Mainland and Hong Kong markets with global investors. China Securities Index Company Limited is commissioned to calculate, provide index maintenance and dissemination service for the CES indices.

For further information on CESC, please visit the website at www.cesc.com.

Ends

Appendix 1

Overview of CES HK Biotechnology Index

Index Abbreviation	CES HK Biotech
Index Code	CESHKB
Constituent Eligibility	Stocks with a primary or secondary listing on the Main Board of The Stock Exchange of Hong Kong, listed under Chapter 18A of The Stock Exchange of Hong Kong's Main Board Listing Rules or classified as a "Biotechnology Company" according to the Industry Classification, and with average market capitalisation of at least \$1.5 billion during the most recent year.
Launch Date	14 November 2018
Base Date	12 December 2014
Base Value	2000
Number of stocks	Variable
Calculation Methodology	Free float-adjusted market capitalisation weighted, with a: 10% cap if there are 20 or more constituents, 15% cap if there are 8 to 19 constituents, 25% cap if there are 5 to 7 constituents. (if there are less than 5 constituents, the constituents will be equally weighted)
Calculation and Dissemination	Real Time at 5-second intervals
Review Frequency	Half-yearly
Real-time Price Index (Currency)	HKD
End of Day Index (Currency)	HKD & CNY
Total Return Index (Currency)	HKD & CNY

Appendix 2

CES HK Biotechnology Index's Constituents and Weightings

(As at 13 November 2018)

Stock Code	Stock Name	Weighting (%)
00775.HK	CKLIFE SCIENCES	2.19
01061.HK	ESSEX BIO-TECH	6.12
01177.HK	SINO BIOPHARM	17.12
01530.HK	3SBIO	16.38
01548.HK	GENSCRIPT BIO	13.97
01672.HK	ASCLETIS-B	5.45
02269.HK	WUXI BIO	13.17
02552.HK	HUA MEDICINE-B	10.72
06160.HK	BEIGENE-B	11.48
06826.HK	HAOHAI BIOTEC	3.40